A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B

H. L.Y. Chan, D. Messinger, G. V. Papatheodoridis, M. Cornberg, Q. Xie, T. Piratvisuth, H. Ren, P. T. Kennedy, A. Thompson, A. Caputo, G. Bakalos, V. Pavlovic, P. Lampertico

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Peginterferon induces off-treatment responses in approximately one-third of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Aim: To develop an easy-to-use baseline prediction score to identify hepatitis B virus (HBV) genotype B-/C-infected HBeAg-positive Asian patients likely to respond to peginterferon alfa-2a. Methods: Generalised additive models, multiple logistic regression (MLR) analysis and internal validation methods were applied to data from 647 HBeAg-positive patients from China, Hong Kong and Taiwan to develop a scoring system to predict response 24 weeks after completing a 48-week course of peginterferon alfa-2a. Results: Five baseline factors (age, sex, alanine aminotransferase ratio, hepatitis B surface antigen (HBsAg) level and HBV DNA level) were retained in the final MLR for HBeAg seroconversion and used to develop a scoring system from 0 to 7. Among patients with scores of 0-1, 2-3, 4 or ≥5, HBeAg seroconversion was achieved in 6.4% (6/94), 23.0% (61/265), 36.4% (67/184) and 54.8% (57/104), respectively, and a combined response (HBeAg seroconversion plus HBV DNA <2000 IU/mL) in 5.3% (5/94), 12.8% (34/265), 25.0% (46/184) and 36.5% (38/104), respectively. Among patients with scores of 0-1, 2-3, 4 or ≥5, 57.0% (53/93), 12.3% (31/253), 3.4% (6/178) and 1.0% (1/100) had HBsAg ≥20 000 IU/mL at treatment Week 12; only 3/91 (3.3%) with HBsAg ≥20 000 IU/mL experienced a combined response at 24 weeks post-treatment (negative predictive value = 97% [88/91]). Conclusion: A pre-treatment scoring system using readily available baseline characteristics identifies HBeAg-positive Asian patients likely to experience sustained HBeAg seroconversion after treatment with peginterferon alfa-2a.

Original languageEnglish
Pages (from-to)547-555
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume48
Issue number5
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Hepatitis B e Antigens
Chronic Hepatitis B
Hepatitis B Surface Antigens
Hepatitis B virus
Logistic Models
Therapeutics
Sex Factors
peginterferon alfa-2a
Age Factors
DNA
Hong Kong
Alanine Transaminase
Taiwan
China
Genotype
Regression Analysis
Seroconversion

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Cite this

A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. / Chan, H. L.Y.; Messinger, D.; Papatheodoridis, G. V.; Cornberg, M.; Xie, Q.; Piratvisuth, T.; Ren, H.; Kennedy, P. T.; Thompson, A.; Caputo, A.; Bakalos, G.; Pavlovic, V.; Lampertico, P.

In: Alimentary Pharmacology and Therapeutics, Vol. 48, No. 5, 01.09.2018, p. 547-555.

Research output: Contribution to journalArticle

Chan, HLY, Messinger, D, Papatheodoridis, GV, Cornberg, M, Xie, Q, Piratvisuth, T, Ren, H, Kennedy, PT, Thompson, A, Caputo, A, Bakalos, G, Pavlovic, V & Lampertico, P 2018, 'A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B', Alimentary Pharmacology and Therapeutics, vol. 48, no. 5, pp. 547-555. https://doi.org/10.1111/apt.14862
Chan, H. L.Y. ; Messinger, D. ; Papatheodoridis, G. V. ; Cornberg, M. ; Xie, Q. ; Piratvisuth, T. ; Ren, H. ; Kennedy, P. T. ; Thompson, A. ; Caputo, A. ; Bakalos, G. ; Pavlovic, V. ; Lampertico, P. / A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. In: Alimentary Pharmacology and Therapeutics. 2018 ; Vol. 48, No. 5. pp. 547-555.
@article{e0afaed868cc4c3b96156adde69ff380,
title = "A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B",
abstract = "Background: Peginterferon induces off-treatment responses in approximately one-third of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Aim: To develop an easy-to-use baseline prediction score to identify hepatitis B virus (HBV) genotype B-/C-infected HBeAg-positive Asian patients likely to respond to peginterferon alfa-2a. Methods: Generalised additive models, multiple logistic regression (MLR) analysis and internal validation methods were applied to data from 647 HBeAg-positive patients from China, Hong Kong and Taiwan to develop a scoring system to predict response 24 weeks after completing a 48-week course of peginterferon alfa-2a. Results: Five baseline factors (age, sex, alanine aminotransferase ratio, hepatitis B surface antigen (HBsAg) level and HBV DNA level) were retained in the final MLR for HBeAg seroconversion and used to develop a scoring system from 0 to 7. Among patients with scores of 0-1, 2-3, 4 or ≥5, HBeAg seroconversion was achieved in 6.4{\%} (6/94), 23.0{\%} (61/265), 36.4{\%} (67/184) and 54.8{\%} (57/104), respectively, and a combined response (HBeAg seroconversion plus HBV DNA <2000 IU/mL) in 5.3{\%} (5/94), 12.8{\%} (34/265), 25.0{\%} (46/184) and 36.5{\%} (38/104), respectively. Among patients with scores of 0-1, 2-3, 4 or ≥5, 57.0{\%} (53/93), 12.3{\%} (31/253), 3.4{\%} (6/178) and 1.0{\%} (1/100) had HBsAg ≥20 000 IU/mL at treatment Week 12; only 3/91 (3.3{\%}) with HBsAg ≥20 000 IU/mL experienced a combined response at 24 weeks post-treatment (negative predictive value = 97{\%} [88/91]). Conclusion: A pre-treatment scoring system using readily available baseline characteristics identifies HBeAg-positive Asian patients likely to experience sustained HBeAg seroconversion after treatment with peginterferon alfa-2a.",
author = "Chan, {H. L.Y.} and D. Messinger and Papatheodoridis, {G. V.} and M. Cornberg and Q. Xie and T. Piratvisuth and H. Ren and Kennedy, {P. T.} and A. Thompson and A. Caputo and G. Bakalos and V. Pavlovic and P. Lampertico",
year = "2018",
month = "9",
day = "1",
doi = "10.1111/apt.14862",
language = "English",
volume = "48",
pages = "547--555",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B

AU - Chan, H. L.Y.

AU - Messinger, D.

AU - Papatheodoridis, G. V.

AU - Cornberg, M.

AU - Xie, Q.

AU - Piratvisuth, T.

AU - Ren, H.

AU - Kennedy, P. T.

AU - Thompson, A.

AU - Caputo, A.

AU - Bakalos, G.

AU - Pavlovic, V.

AU - Lampertico, P.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background: Peginterferon induces off-treatment responses in approximately one-third of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Aim: To develop an easy-to-use baseline prediction score to identify hepatitis B virus (HBV) genotype B-/C-infected HBeAg-positive Asian patients likely to respond to peginterferon alfa-2a. Methods: Generalised additive models, multiple logistic regression (MLR) analysis and internal validation methods were applied to data from 647 HBeAg-positive patients from China, Hong Kong and Taiwan to develop a scoring system to predict response 24 weeks after completing a 48-week course of peginterferon alfa-2a. Results: Five baseline factors (age, sex, alanine aminotransferase ratio, hepatitis B surface antigen (HBsAg) level and HBV DNA level) were retained in the final MLR for HBeAg seroconversion and used to develop a scoring system from 0 to 7. Among patients with scores of 0-1, 2-3, 4 or ≥5, HBeAg seroconversion was achieved in 6.4% (6/94), 23.0% (61/265), 36.4% (67/184) and 54.8% (57/104), respectively, and a combined response (HBeAg seroconversion plus HBV DNA <2000 IU/mL) in 5.3% (5/94), 12.8% (34/265), 25.0% (46/184) and 36.5% (38/104), respectively. Among patients with scores of 0-1, 2-3, 4 or ≥5, 57.0% (53/93), 12.3% (31/253), 3.4% (6/178) and 1.0% (1/100) had HBsAg ≥20 000 IU/mL at treatment Week 12; only 3/91 (3.3%) with HBsAg ≥20 000 IU/mL experienced a combined response at 24 weeks post-treatment (negative predictive value = 97% [88/91]). Conclusion: A pre-treatment scoring system using readily available baseline characteristics identifies HBeAg-positive Asian patients likely to experience sustained HBeAg seroconversion after treatment with peginterferon alfa-2a.

AB - Background: Peginterferon induces off-treatment responses in approximately one-third of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Aim: To develop an easy-to-use baseline prediction score to identify hepatitis B virus (HBV) genotype B-/C-infected HBeAg-positive Asian patients likely to respond to peginterferon alfa-2a. Methods: Generalised additive models, multiple logistic regression (MLR) analysis and internal validation methods were applied to data from 647 HBeAg-positive patients from China, Hong Kong and Taiwan to develop a scoring system to predict response 24 weeks after completing a 48-week course of peginterferon alfa-2a. Results: Five baseline factors (age, sex, alanine aminotransferase ratio, hepatitis B surface antigen (HBsAg) level and HBV DNA level) were retained in the final MLR for HBeAg seroconversion and used to develop a scoring system from 0 to 7. Among patients with scores of 0-1, 2-3, 4 or ≥5, HBeAg seroconversion was achieved in 6.4% (6/94), 23.0% (61/265), 36.4% (67/184) and 54.8% (57/104), respectively, and a combined response (HBeAg seroconversion plus HBV DNA <2000 IU/mL) in 5.3% (5/94), 12.8% (34/265), 25.0% (46/184) and 36.5% (38/104), respectively. Among patients with scores of 0-1, 2-3, 4 or ≥5, 57.0% (53/93), 12.3% (31/253), 3.4% (6/178) and 1.0% (1/100) had HBsAg ≥20 000 IU/mL at treatment Week 12; only 3/91 (3.3%) with HBsAg ≥20 000 IU/mL experienced a combined response at 24 weeks post-treatment (negative predictive value = 97% [88/91]). Conclusion: A pre-treatment scoring system using readily available baseline characteristics identifies HBeAg-positive Asian patients likely to experience sustained HBeAg seroconversion after treatment with peginterferon alfa-2a.

UR - http://www.scopus.com/inward/record.url?scp=85051264223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051264223&partnerID=8YFLogxK

U2 - 10.1111/apt.14862

DO - 10.1111/apt.14862

M3 - Article

VL - 48

SP - 547

EP - 555

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -